EP1501534A2 — Desmopressin in an orodispersible dosage form
Assigned to Ferring BV · Expires 2005-02-02 · 21y expired
What this patent protects
Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form which provides for a rapid dispersion of the active substance in the oral cavity. Thereby, desmopressin may be absorbed across the sublingual, buccal and/or gingival muco…
USPTO Abstract
Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form which provides for a rapid dispersion of the active substance in the oral cavity. Thereby, desmopressin may be absorbed across the sublingual, buccal and/or gingival mucosa, and/or from the gastrointestinal tract for systemic distribution. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. A process for the production of the dosage form by subliming solvent from a composition comprising desmopressin and a solution of carrier material is also provided.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.